Rejian Medicine completed a C1 round of financing worth 210 million yuan.

Recently, Rejoin Therapeutics, a general cell therapy platform company, announced the completion of a C1 round of financing worth RMB 210 million. This round of financing was jointly led by Photosynthetic Venture Capital and Apricot Capital. The raised funds will be mainly used for promoting the company's core clinical pipelines, continuously upgrading the AI + chemical induction platform, building a large-scale production system, conducting global clinical development, and laying out international commercial cooperation.